Compare ARW & BLLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARW | BLLN |
|---|---|---|
| Founded | 1935 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electronic Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.0B |
| IPO Year | N/A | 2025 |
| Metric | ARW | BLLN |
|---|---|---|
| Price | $112.20 | $112.80 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $102.00 | ★ $138.67 |
| AVG Volume (30 Days) | ★ 491.5K | 203.3K |
| Earning Date | 10-30-2025 | 12-09-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 0.79 | N/A |
| EPS | ★ 9.05 | N/A |
| Revenue | ★ $29,389,382,000.00 | $209,032,000.00 |
| Revenue This Year | $9.50 | N/A |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | $12.42 | ★ N/A |
| Revenue Growth | 3.16 | ★ 112.72 |
| 52 Week Low | $86.50 | $88.00 |
| 52 Week High | $134.74 | $138.70 |
| Indicator | ARW | BLLN |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | N/A |
| Support Level | $101.79 | N/A |
| Resistance Level | $108.74 | N/A |
| Average True Range (ATR) | 2.34 | 0.00 |
| MACD | 1.11 | 0.00 |
| Stochastic Oscillator | 94.31 | 0.00 |
Arrow Electronics Inc. is a provider of products, services, and solutions to industrial and commercial users of electronic components and enterprise computing solutions. It has one of the world's broadest portfolios of product offerings available from electronic components and enterprise computing solutions suppliers, coupled with a range of services, solutions, and software, the company helps industrial and commercial customers introduce products, reduce their time to market, and enhance their overall competitiveness. The company has two business segments, the components business and the enterprise computing solutions.
BillionToOne Inc is a precision diagnostics company revolutionizing molecular testing with its patented Quantitative Counting Templates (QCT) platform. This technology enables ultrasensitive, single-molecule DNA quantification, making genetic testing more accurate, affordable, and accessible. The company serves prenatal screening and oncology markets with non-invasive tests that detect fetal genetic risks and monitor cancer therapy response.